A roundup of some of the biggest recent stories from German pharma, including the latest on beleaguered Bayer CEO Werner Baumann, Merck KGaA’s latest investments in France and Germany, and STADA securing the first authorized treatment in Europe for the…
Kevin Rufang Huang, president and founder of the Chinese Organization for Rare Disorders (CORD), outlines the findings of the first ever analysis into rare disease public insurance coverage across key…
Drawing on her experience as rare disease patient advocacy group SYNGAP1 Foundation’s founder and former president, Monica Weldon argues for the need to standardize genomic testing practices, warns against the…
Bill Sibold, Executive Vice President and Head of Sanofi Genzyme, highlights the achievements of the company’s Rare Humanitarian Program over the last 30 years, bringing treatments to patients in developing…
Ahmad Abu Dahab became the first Middle East employee for Swedish-headquartered haematology, immunology and specialty care player SOBI back in 2012 and now serves as VP for the entire Middle East, Turkey, and Northern Africa region. Abu Dahab explains some of the key trends at play in the rare diseases space and how SOBI works in tandem with health authorities…
IFET is a unique institution within Greece that acts as the country’s mechanism for securing access to rare disease therapies not available in the market. The organisation also works to…
Dompé’s Chief Operating Officer, Eriona Gjinukaj, responsible for creating the Italian mid-cap’s US affiliate, reveals the challenges and rewards of that experience and explains how she saw the company go…
Writing in the March edition of DIA’s Global Forum magazine, Judith Glennie examines the findings of Health Canada’s consultation with Canadians on what a national strategy for high-cost rare disease…
The National Organization for Rare Disorders (NORD) is set to host its annual Rare Diseases and Orphan Products Breakthrough Summit on October 18-19th. Ahead of the Summit, the Chair of…
Few stakeholders are better placed to assess the landscape for rare disease therapies across the Middle East and North Africa (MENA) region than Karim Smaira and Kamel Ghammachi of Genpharm,…
In Europe, patient access to Orphan Medicinal Products (OMP) for the treatment of rare diseases remains inequitable. With the common goal of ensuring broader and faster access to OMPs across…
Monica Weldon draws on her own experience as a rare disease patient advocacy group CEO to outline how such groups can work collaboratively with other stakeholders in drug development to…
From humble origins, taiba can now count on a unique two decades of experience in bringing innovative rare disease products to patients across the MENA region. The Dubai headquartered company,…
See our Cookie Privacy Policy Here
